Form D · Biotechnology
Tansna Therapeutics, Inc.
St. Louis, MO · CIK 0001587426
Offering snapshot reported Sep 25, 2013 · SEC filing
- Reported sold
- Yet to sell Offering amount: $850K
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 25, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-203528
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| NA | None |
Source: Form D, filed Sep 25, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Max Baker | Director |
| Kathleen Beckmann | Executive |
| Charles Bolten | Director |
| George Capps | Executive |
| Rajesh Devraj | Director |
| Robert Karr | Executive |
| Alan Mac Innes | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4320 Forest Park Avenue Suite 303
St. Louis, MO, 63108
St. Louis, MO, 63108